Calmare Therapeutics Inc (fka CTTC)

[powderbum]

ASCO

http://chicago2013.asco.org/sites/chicago2013.asco.org/files/AM13-program-lowres.pdf

Responding to Common Concerns of Patients with Cancer: What's New—In a Nutshell—From Research to Therapeutic Strategies

Gretchen Genevieve Kimmick, MD, MS—Chair
Duke University Medical Center
Charles L. Loprinzi, MD
Mayo Clinic
Leslie R. Schover, PhD
The University of Texas MD Anderson Cancer Center
Sydney Morss Dy, MD, MSc
The Johns Hopkins University School of Medicine
Donna B. Greenberg, MD
Massachusetts General Hospital
Atilla Soran, MD, MPH
Magee-Womens Hospital of the University of Pittsburgh Medical Center


Patient and Survivor Care: What's New? Dr. Charles Loprinzi, Mayo Clinic.(currently doing three studies on Calmare) What might he talk about? Calmare? He submitted an abstract last year at ASCO with positive results on Calmare.

http://www.clinicaltrials.gov/ct2/show/NCT01290224?term=scrambler+therapy&rank=1

http://www.clinicaltrials.gov/ct2/show/NCT01347736?term=scrambler+therapy&rank=2

http://www.clinicaltrials.gov/ct2/show/NCT01347723?term=scrambler+therapy&rank=3



Calmare/Scrambler therapy American Society of Clinical Oncology (ASCO)
Pilot study of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.
Sub-category:
Symptom Management/Supportive Care/Palliative Care
Category:
Patient and Survivor Care
Meeting:
2012 ASCO Annual Meeting
Abstract No:
9075
Citation:
J Clin Oncol 30, 2012 (suppl; abstr 9075)
Attend this session at the
ASCO Annual Meeting!

Session: Patient and Survivor Care

Type: General Poster Session

Time: Saturday June 2, 8:00 AM to 12:00 PM

Location: S Hall A2 Personalize your Annual Meeting experience with a suggested or customized itinerary!


Author(s): Deirdre R. Pachman, Breanna M. Linquist, Debra L. Barton, Kelliann C. Fee-Schroeder, Thomas J. Smith, Daniel Honore Lachance, Heshan Liu, Drew K. Seisler, Charles L. Loprinzi; Mayo Clinic, Rochester, MN; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Abstract Disclosures


Abstract:
Background: Chemotherapy-induced peripheral neuropathy (CIPN), a common dose-limiting side effect of chemotherapy, remains without known effective interventions. Preliminary data support that Scrambler therapy, a device which treats pain via non-invasive cutaneous electrostimulation, is beneficial for the treatment of CIPN. This pilot trial was performed to investigate the effect of Scrambler therapy for the treatment of CIPN. Methods: Eligible patients included those age =18 years, ECOG PS =2, life expectancy =3 months, with pain or CIPN symptoms of =1 month duration and tingling or pain =4/10 during the prior week. Patients were treated with Scrambler therapy to the affected area for up to 10 daily 30 minute sessions. Symptoms were monitored daily during therapy using a questionnaire to measure symptoms of neuropathy with a numerical analogue scale. Results: We report on the first 11 CIPN patients, enrolled between 7/18/2011 and 12/12/2011, 3 men and 8 women; mean age 57 years. Patients had history of exposure to various chemotherapeutic agents and the majority had symptoms >2 years. The table portrays data at baseline, at the end of the 10 planned days of therapy, and the percent changes from baseline to the end of treatment, regarding patient reported pain, tingling, and numbness over the preceding 24 hours. There were no adverse events. Persistent benefit out to 5 weeks was seen in some patients; maturing data will be available by May 2012. Descriptive summary statistics formed the basis of data analysis. Further patients are being entered on this trial. Conclusions: Scrambler therapy appears to be beneficial in the treatment of CIPN. A prospective placebo-controlled clinical trial should be performed to confirm these preliminary findings.